Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_assertion type Assertion NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_head.
- NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_assertion description "[In low-risk MDS/AA patients, the percentage of CD3+ lymphocytes was significantly increased compared to controls (p=0.006 and p=0.001), while the percentage of CD19+ lymphocytes was significantly decreased (p<0.001 and p=0.002); there were no significant differences between MDS/AA and normal controls in other parameters; For low-risk MDS patients, the polarization status of bone marrow CD4+ cells toward Th1 (Th1/Th2) and of CD8+ cells toward Tc1 (Tc1/Tc2) was stronger than that for AA patients (p=0.05 and p<0.001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_provenance.
- NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_assertion evidence source_evidence_literature NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_provenance.
- NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_assertion SIO_000772 20647647 NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_provenance.
- NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_assertion wasDerivedFrom befree-20140225 NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_provenance.
- NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_assertion wasGeneratedBy ECO_0000203 NP575034.RAKbyzDHu31EV1Zp5D5WX-BTyhkZ-1YW8D_5-sbX1ryrQ130_provenance.